Effects of Insulin Glargine vs Thiazolidinediones (TZDs) on Glycemic and Lipid Variables in T2DM

被引：0

|

作者：

Hollander, Priscilla

Rosenberg, Noah

Chaudhuri, Ajay

Nesto, Richard W.

Rosenstock, Julio

Meneghini, Luigi F.

Dandona, Paresh

Riddle, Matthew C.

机构：

来源：

DIABETES | 2009年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：A522 / A522

页数：1

相关论文

共 50 条

[1] Effects of Insulin Glargine vs Thiazolidinediones on Glycemic and Lipid Variables in Type 2 Diabetes Mellitus (T2DM): The Impact of Obesity
Meneghini, Luigi F.
Rosenberg, Noah
Hollander, Priscilla
Rosenstock, Julio
Riddle, Matthew C.
Nesto, Richard W.
Dandona, Paresh
[J]. DIABETES, 2009, 58 : A523 - A523
[2] Free fatty acid (FFA) changes with insulin glargine (GLAR) vs thiazolidinediones (TZDs) according to baseline A1C in T2DM
Schwartz, Sherwyn
Cohen, Jay
Traylor, Louise
Rosenstock, Julio
[J]. DIABETES, 2007, 56 : A232 - A232
[3] Different Effects of Insulin Glargine Given Morning vs. Evening in T2DM
Porcellati, Francesca
Lucidi, Paola
Cioli, Patrizia
Marzotti, Stefania
Andreoli, Anna Marinelli
Bolli, Geremia B.
Fanelli, Carmine G.
[J]. DIABETES, 2012, 61 : A249 - A249
[4] Effects of insulin glargine vs thiazolidinediones on glycaemic and lipid variables in type 2 diabetes mellitus: the impact of obesity
Dandona, P.
Rosenberg, N.
Hollander, P.
Rosenstock, J.
Meneghini, L.
[J]. DIABETOLOGIA, 2009, 52 : S351 - S351
[5] Influence of Gender on Glycemic Control and Hypoglycemia in T2DM Patients Initiating Insulin Glargine
Kautzky-Willer, Alexandra
Traylor, Louise
Landgraf, Wolfgang
Charbonnel, Bernard
[J]. DIABETES, 2015, 64 : A257 - A257
[6] Change in lipid variables with insulin glargine versus pioglitazone in T2DM patients inadequately controlled on a sulfonylurea or metformin
McGill, J. B.
Traylor, L.
Dwarakanathan, A.
[J]. DIABETOLOGIA, 2007, 50 : S506 - S506
[7] Similar glycemic control is achieved after discontinuation of thiazolidinediones (TZDs) and metformin (MET) in patients initiating insulin glargine (GLAR) as add-on therapy for type 2 Diabetes (T2DM): The GOAL A1C study
Herman, WH
Kennedy, L
Harris, A
Strange, P
[J]. DIABETES, 2005, 54 : A140 - A140
[8] The Impact of Age and Disease Duration on Glycemic Control and Lipid Profile: Insulin Glargine vs Thiazolidinediones in Type 2 Diabetes
Rosenstock, Julio
Rosenberg, Noah
Riddle, Matthew C.
Meneghini, Luigi F.
Chaudhuri, Ajay
[J]. DIABETES, 2009, 58 : A539 - A539
[9] Physiologic Dose Response Effects of Insulin Glargine in Type 2 Diabetes (T2DM
Wang, Zhihui
Briscoe, Vanessa J.
Hedrington, Maka S.
Gogitidze, Nino
Richardson, Antoinette
Ertl, Andrew C.
Davis, Stephen N.
[J]. DIABETES, 2009, 58 : A150 - A150
[10] Effect of Lixisenatide vs. Liraglutide on Glycemic Control, Gastric Emptying, and Safety Parameters in Optimized Insulin Glargine T2DM ± Metformin
Meier, Juris
Rosenstock, Julio
Hincelin-Mery, Agnes
Royduval, Christine
Delfolie, Astrid
Coester, Hans-Veit
Forst, Thomas
Kapitza, Christoph
[J]. DIABETES, 2014, 63 : A262 - A262

← 1 2 3 4 5 →